Claims for Patent: 12,544,379

Summary for Patent: 12,544,379

Title:	Combination therapy using ribociclib and fulvestrant for the treatment of HR+ breast cancer
Abstract:	The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.
Inventor(s):	Yan Chen, Xizhong Huang, Sunkyu Kim
Assignee:	Novartis AG
Application Number:	US18/469,975
Patent Claims:	1. A method of treating HR+ breast cancer in a human, comprising administering to the human therapeutically effective levels of Compound A1, or a pharmaceutically acceptable salt thereof: and therapeutically effective levels of fulvestrant. 2. The method of claim 1, wherein a jointly therapeutically effective amount of Compound A1, or a pharmaceutically acceptable salt thereof, and fulvestrant is administered, and the administration provides to the human 200 mg/day, 400 mg/day or 600 mg/day of Compound A1. 3. The method of claim 2, wherein the administration provides to the human 200 mg/day of Compound A1. 4. The method of claim 2, wherein the administration provides to the human 400 mg/day of Compound A1. 5. The method of claim 2, wherein the administration provides to the human 600 mg/day of Compound A1. 6. A method of administering Compound A1, or a pharmaceutically acceptable salt thereof: and fulvestrant to a human HR+ breast cancer patient, the method comprising administering Compound A1 and fulvestrant to the patient to provide therapeutically effective levels of Compound A1 and fulvestrant in the patient. 7. The method of claim 6, wherein the administration provides to the human 200 mg/day, 400 mg/day or 600 mg/day of Compound A1. 8. The method of claim 7, wherein the administration provides to the human 200 mg/day of Compound A1. 9. The method of claim 7, wherein the administration provides to the human 400 mg/day of Compound A1. 10. The method of claim 7, wherein the administration provides to the human 600 mg/day of Compound A1.